154 related articles for article (PubMed ID: 21571861)
41. [Association between genetic polymorphism in DNA repair genes XRCC3 and risks of laryngeal and hypopharyngeal carcinomas].
Wen SX; Zhang XM; Tang PZ; Zhao D; Guo YL; Tan W; Lin DX
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Nov; 42(11):856-9. PubMed ID: 18300452
[TBL] [Abstract][Full Text] [Related]
42. Hyperthermia inhibited the migration of tongue squamous cell carcinoma through TWIST2.
Tang YL; Jiang J; Liu J; Zheng M; He YW; Chen W; Fan YL; Chen QM; Liao CH; Liang XH
J Oral Pathol Med; 2015 May; 44(5):337-44. PubMed ID: 25048179
[TBL] [Abstract][Full Text] [Related]
43. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
De Castro G; Pasini FS; Siqueira SA; Ferraz AR; Villar RC; Snitcovsky IM; Federico MH
Oncol Rep; 2011 Mar; 25(3):693-9. PubMed ID: 21206986
[TBL] [Abstract][Full Text] [Related]
44. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
45. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer.
Toustrup K; Sørensen BS; Nordsmark M; Busk M; Wiuf C; Alsner J; Overgaard J
Cancer Res; 2011 Sep; 71(17):5923-31. PubMed ID: 21846821
[TBL] [Abstract][Full Text] [Related]
46. Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC).
Zhang F; Li Y; Zhang H; Huang E; Gao L; Luo W; Wei Q; Fan J; Song D; Liao J; Zou Y; Liu F; Liu J; Huang J; Guo D; Ma C; Hu X; Li L; Qu X; Chen L; Yu X; Zhang Z; Wu T; Luu HH; Haydon RC; Song J; He TC; Ji P
Oncotarget; 2017 Feb; 8(8):12968-12982. PubMed ID: 28099902
[TBL] [Abstract][Full Text] [Related]
47. Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.
Bae WJ; Koo BS; Lee SH; Kim JM; Rho YS; Lim JY; Moon JH; Cho JH; Lim YC
Br J Cancer; 2017 Dec; 117(12):1810-1818. PubMed ID: 29096401
[TBL] [Abstract][Full Text] [Related]
48. Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma.
Vakili Saatloo M; Aghbali AA; Koohsoltani M; Yari Khosroushahi A
Gene; 2019 Sep; 714():143997. PubMed ID: 31348981
[TBL] [Abstract][Full Text] [Related]
49. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
Ishiguro R; Fujii M; Yamashita T; Tashiro M; Tomita T; Ogawa K; Kameyama K
Anticancer Res; 2003; 23(6D):5213-20. PubMed ID: 14981992
[TBL] [Abstract][Full Text] [Related]
50. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
51. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma.
Kurth I; Hein L; Mäbert K; Peitzsch C; Koi L; Cojoc M; Kunz-Schughart L; Baumann M; Dubrovska A
Oncotarget; 2015 Oct; 6(33):34494-509. PubMed ID: 26460734
[TBL] [Abstract][Full Text] [Related]
52. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
53. Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancer.
Gan HK; Bernstein LJ; Brown J; Ringash J; Vakilha M; Wang L; Goldstein D; Kim J; Hope A; O'Sullivan B; Waldron J; Abdul Razak AR; Chen EX; Siu LL
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):126-34. PubMed ID: 20708851
[TBL] [Abstract][Full Text] [Related]
54. Mammalian target of rapamycin and head and neck squamous cell carcinoma.
Liao YM; Kim C; Yen Y
Head Neck Oncol; 2011 Apr; 3():22. PubMed ID: 21513566
[TBL] [Abstract][Full Text] [Related]
55. IL-6 antisense-mediated growth inhibition in a head and neck squamous cell carcinoma cell line.
Bran G; Götte K; Riedel K; Hörmann K; Riedel F
In Vivo; 2011; 25(4):579-84. PubMed ID: 21708999
[TBL] [Abstract][Full Text] [Related]
56. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck.
Huang KK; Jang KW; Kim S; Kim HS; Kim SM; Kwon HJ; Kim HR; Yun HJ; Ahn MJ; Park KU; Ramnarayanan K; McPherson JR; Zhang S; Rhee JK; Vettore AL; Das K; Ishimoto T; Kim JH; Koh YW; Kim SH; Choi EC; Teh BT; Rozen SG; Kim TM; Tan P; Cho BC
Sci Rep; 2016 Jan; 6():19552. PubMed ID: 26790612
[TBL] [Abstract][Full Text] [Related]
57. Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice.
Zhao XG; Sun RJ; Yang XY; Liu DY; Lei DP; Jin T; Pan XL
PLoS One; 2015; 10(4):e0126147. PubMed ID: 25923669
[TBL] [Abstract][Full Text] [Related]
58. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
59. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo.
Senkal CE; Ponnusamy S; Rossi MJ; Sundararaj K; Szulc Z; Bielawski J; Bielawska A; Meyer M; Cobanoglu B; Koybasi S; Sinha D; Day TA; Obeid LM; Hannun YA; Ogretmen B
J Pharmacol Exp Ther; 2006 Jun; 317(3):1188-99. PubMed ID: 16510697
[TBL] [Abstract][Full Text] [Related]
60. Establishment and characterization of a novel hypopharyngeal squamous cell carcinoma cell line CZH1 with genetic abnormalities.
Ma J; Zhu X; Heng Y; Ding X; Tao L; Lu L
Hum Cell; 2024 Mar; 37(2):546-559. PubMed ID: 38280070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
